Nuclear matrix targets for anticancer agents.
The nuclear matrix of eukaryotic cells comprises a dynamic framework on which DNA is organized into discrete functional units of replication and transcription. There is growing evidence that matrix-associated DNA and proteins are direct targets of a wide range of clinically active anticancer agents. DNA associated with matrix-bound replication and transcription sites has a relatively open conformation and is preferentially damaged by ionizing radiation and certain alkylating agents. Fludarabine phosphate, a purine antimetabolite, inhibits DNA replication by blocking the synthesis of matrix-associated primer RNA and RNA-primed Okazaki fragments. VM-26 and m-AMSA appear to interact specifically with nuclear matrix topoisomerase II, and one mechanism of cellular resistance to these agents is associated with depletion of the matrix enzyme. Studies of the interactions of anticancer agents with targets in the nuclear matrix should provide further insight into the mechanisms by which these agents exert their therapeutic effects.